Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides

Nat Med. 1995 Nov;1(11):1179-83. doi: 10.1038/nm1195-1179.


The cure of micrometastases following surgery is the major goal of cancer immunotherapy. We have recently isolated tumour-associated antigen (TAA) peptides, MUT 1 and MUT 2, derived from a mutated connexin 37 gap-junction protein, from the malignant 3LL-D122 murine lung carcinoma. We now report that synthetic MUT 1 or MUT 2 induces effective antitumour cytoxic T lymphocytes. Peptide vaccines protect mice from spontaneous metastases of 3LL-D122 tumours. Moreover, peptide vaccines reduce metastatic loads in mice carrying pre-established micrometastases. Tumour-specific immunity was primarily mediated by CD8+ T cells. This is the first evidence that peptide therapy may be effective in treatment of residual tumours and provides a rationale for the development of peptide vaccines as a modality for cancer therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Neoplasm / immunology*
  • CD4-Positive T-Lymphocytes / immunology
  • Immunotherapy*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / secondary
  • Lung Neoplasms / therapy*
  • Mice
  • Mice, Inbred C57BL
  • Neoplasm Metastasis / prevention & control
  • Oligopeptides / immunology*
  • Peptide Fragments / chemical synthesis
  • Peptide Fragments / immunology*
  • Survival Analysis
  • T-Lymphocytes, Cytotoxic / immunology
  • Vaccination*


  • Antigens, Neoplasm
  • MUT 1 peptide
  • MUT 2 peptide
  • Oligopeptides
  • Peptide Fragments